Table 2: Univariate analysis of risk factors associated with BM in NSCLC patient.
|
|
|
Without BM (N=255) |
With BM (n=52) |
OR |
95%CI |
p |
|
CI |
Yes |
160 |
44 |
3.266 |
1.475-7.231 |
0.004 |
|
No |
95 |
8 |
||||
|
Primary tumor location (lobe) |
Middle |
14 |
9 |
3.603 |
1.468-8.845 |
0.005 |
|
Upper or Lower |
241 |
43 |
||||
|
Histology (type) |
180 |
46 |
3.194 |
1.309-7.797 |
0.011 |
|
|
Not Ad |
75 |
6 |
||||
|
T status |
T1-T2 |
181 |
24 |
2.854 |
1.553-5.245 |
0.001 |
|
T3-T4 |
74 |
28 |
||||
|
LN status |
N0-N1 |
121 |
10 |
3.793 |
1.824-7.887 |
<0.001 |
|
N2-N3 |
134 |
42 |
||||
|
D-D (ng/ml) |
>500 |
44 |
16 |
2.131 |
1.088-4.176 |
0.027 |
|
≤500 |
211 |
36 |
||||
|
CEA (ng/ml) |
>5 |
114 |
36 |
2.783 |
1.470-5.270 |
0.002 |
|
≤5 |
141 |
16 |
||||
|
CA125 (U/ml) |
>35 |
80 |
30 |
2.983 |
1.620-5.492 |
<0.001 |
|
≤35 |
175 |
22 |
BM: brain metastasis; CI: cerebral infarction; D-D: D-Dimer; CEA: carcinoembryonic antigen; CA125: carbohydrate antigen 125.